Ticker
ACIU

Price
3.22
Stock movement down
-0.30 (-8.52%)
Company name
AC Immune Ltd
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
268.59M
Ent verdi
232.14M
Pris/omsetning
-
Pris/bok
1.25
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-52.51%
3 års avkastning
-14.93%
5 års avkastning
-16.64%
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

ACIU betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok1.25
EV i forhold til salg-

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall83.41M
EPS (TTM)-0.90
FCF per aksje (TTM)-0.88

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-80.59M
Netto inntekt (TTM)-75.11M
EPS (TTM)-0.90
EPS (1 år fremover)-0.33

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter57.84M
Netto fordringer418.00K
Samlede omløpsmidler177.06M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler235.52M
Leverandørgjeld501.00K
Kortsiktig/nåværende langsiktig gjeld2.77M
Sum kortsiktig gjeld11.91M
Sum gjeld21.39M
Aksjonærenes egenkapital214.13M
Netto varige driftsmidler163.72M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-71.49M
Kapitalutgifter (TTM)2.38M
Fri kontantstrøm (TTM)-73.88M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-35.08%
Avkastning på eiendeler-31.89%
Avkastning på investert kapital-34.98%
Kontantavkastning på investert kapital-34.41%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning3.50
Daglig høy3.52
Daglig lav3.16
Daglig volum101K
Tidenes høyeste19.30
1 år analytikerestimat11.41
Beta0.71
EPS (TTM)-0.90
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon7 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACIUS&P500
Nåværende prisfall fra toppnotering-83.32%-12.18%
Høyeste prisfall-87.82%-56.47%
Dato for høyeste fall16 Jun 20229 Mar 2009
Gj.snittlig fall fra topp-59.30%-11.38%
Gj.snittlig tid til ny topp497 days12 days
Maks tid til ny topp1487 days1805 days
SELSKAPSOPPLYSNINGER
ACIU (AC Immune Ltd) company logo
Markedsverdi
268.59M
Markedsverdi kategori
Small-cap
Beskrivelse
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Ansatte
0
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Andrea Pfeifer
Land
USA
By
Lausanne
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product deve...
26. september 2022
Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enha...
1. september 2022
Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine approach, AC Immune is advancing three clinical-sta...
24. august 2022
Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccinati...
11. august 2022
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed a...
2. august 2022
A look at the shareholders of AC Immune SA ( NASDAQ:ACIU ) can tell us which group is most powerful. Institutions will...
31. juli 2022
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
28. juli 2022
Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s di...
28. juli 2022
New data from the API ADAD Study to be presented in AAIC Focused Topic SessionNew Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease First-time pres...
22. juli 2022
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ann...
24. juni 2022
Neste side